Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of Ipilimumab (MDX-CTLA4, MDX-010) in Lymphoma.

Trial Profile

A Pilot Study of Ipilimumab (MDX-CTLA4, MDX-010) in Lymphoma.

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Colorectal cancer; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 27 Sep 2010 Actual end date changed from Feb 2010 to Sep 2010 as reported by ClinicalTrials.gov.
    • 09 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top